Stay updated on Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial
Sign up to get notified when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.

Latest updates to the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page
- CheckyesterdayChange DetectedSite revision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a dedicated Locations section listing California, Massachusetts, New Jersey, New York, and Pennsylvania; updated the page revision to v3.3.3 and removed the HHS Vulnerability Disclosure and the individual state location entries.SummaryDifference0.5%

- Check50 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no study content or site functionality has changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check58 days agoChange DetectedRemoved the site-wide notice about a lapse in government funding and NIH operating status. The core study information on the page remains unchanged.SummaryDifference0.3%

- Check72 days agoChange DetectedThe page now includes posted results for NCT03769467, with results reporting dates and outcome measures (ORR, DoR, PFS, OS) added to the record. This updates the study record with new efficacy and safety data beyond the initial details.SummaryDifference0.4%

- Check101 days agoChange DetectedUpgrade to version v3.2.0 with an operational status notice about potential delays and updated links; replaces the previous v3.1.0 reference.SummaryDifference2%

Stay in the know with updates to Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.